

Lorraine O'Driscoll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7114291/publications.pdf>

Version: 2024-02-01

116
papers

21,827
citations

41258

49
h-index

23472

111
g-index

117
all docs

117
docs citations

117
times ranked

30110
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	5.5	6,961
2	Biological properties of extracellular vesicles and their physiological functions. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27066.	5.5	3,973
3	Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. <i>Obesity Reviews</i> , 2015, 16, 1-12.	3.1	1,177
4	Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 30087.	5.5	1,020
5	Three-dimensional cell culture: the missing link in drug discovery. <i>Drug Discovery Today</i> , 2013, 18, 240-249.	3.2	983
6	EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. <i>Nature Methods</i> , 2017, 14, 228-232.	9.0	886
7	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. <i>ACS Nano</i> , 2016, 10, 3886-3899.	7.3	397
8	Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1703244.	5.5	375
9	Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes. <i>PLoS ONE</i> , 2012, 7, e50999.	1.1	367
10	Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. <i>Carcinogenesis</i> , 2013, 34, 2300-2308.	1.3	359
11	Prognostic importance of survivin in breast cancer. <i>British Journal of Cancer</i> , 2003, 88, 1077-1083.	2.9	224
12	The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. <i>Oncotarget</i> , 2016, 7, 45745-45756.	0.8	214
13	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. <i>Oncotarget</i> , 2015, 6, 32774-32789.	0.8	203
14	Intracellular and Extracellular MicroRNAs in Breast Cancer. <i>Clinical Chemistry</i> , 2011, 57, 18-32.	1.5	197
15	Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. <i>European Journal of Cancer</i> , 2013, 49, 1845-1859.	1.3	192
16	miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. <i>Prostate</i> , 2014, 74, 1320-1334.	1.2	188
17	Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications. <i>Cells</i> , 2020, 9, 991.	1.8	178
18	Extracellular vesicles and anti-cancer drug resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 123-136.	3.3	174

#	ARTICLE	IF	CITATIONS
19	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	7.9	170
20	Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12182.	5.5	147
21	ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	5.5	126
22	Biomarkers and Multiple Drug Resistance in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2006, 6, 365-384.	0.8	112
23	The Role of Exosomes in Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 1457-1465.	1.5	105
24	Expanding on Exosomes and Ectosomes in Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2359-2362.	13.9	100
25	Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. <i>Oncolmmunology</i> , 2017, 6, e1362530.	2.1	100
26	Neuromedin U: A Multifunctional Neuropeptide with Pleiotropic Roles. <i>Clinical Chemistry</i> , 2015, 61, 471-482.	1.5	96
27	Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1647027.	5.5	96
28	International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. <i>Cytotherapy</i> , 2020, 22, 482-485.	0.3	94
29	Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. <i>International Journal of Cancer</i> , 2004, 112, 286-294.	2.3	89
30	Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling. <i>Methods in Molecular Biology</i> , 2011, 784, 181-195.	0.4	89
31	Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. <i>BMC Urology</i> , 2009, 9, 6.	0.6	77
32	The future of Extracellular Vesicles as Theranostics – an ISEV meeting report. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1809766.	5.5	77
33	Survivin: Role in Normal Cells and in Pathological Conditions. <i>Current Cancer Drug Targets</i> , 2003, 3, 131-152.	0.8	73
34	2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype. <i>Scientific Reports</i> , 2019, 9, 3788.	1.6	73
35	2-DE difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. <i>Electrophoresis</i> , 2007, 28, 4302-4310.	1.3	71
36	Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 457-462.	1.0	68

#	ARTICLE	IF	CITATIONS
37	Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. <i>British Journal of Pharmacology</i> , 2012, 167, 787-804.	2.7	68
38	A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 479-491.	6.6	68
39	Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 613-625.	1.1	67
40	Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2013, 14, 1104-1112.	1.5	66
41	miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. <i>Molecular Cancer</i> , 2014, 13, 71.	7.9	66
42	Blood-Based Biomarkers for Metabolic Syndrome. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 363-374.	3.1	66
43	Prevalence and prognostic and predictive relevance of PRAME in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 359-365.	1.1	65
44	Lack of prognostic significance of survivin, survivin-1 ^{Ex3} , survivin-2B, galectin-3, bag-1, bax-1 and MRP-1 mRNAs in breast cancer. <i>Cancer Letters</i> , 2003, 201, 225-236.	3.2	63
45	Molecular medicine of microRNAs: structure, function and implications for diabetes. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e24.	1.6	61
46	Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. <i>Molecular Cancer</i> , 2006, 5, 74.	7.9	59
47	Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells. <i>Journal of Endocrinology</i> , 2006, 191, 665-676.	1.2	58
48	A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 79-87.	1.1	55
49	Human bone marrow stem/stromal cell osteogenesis is regulated via mechanically activated osteocyte-derived extracellular vesicles. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1431-1447.	1.6	52
50	Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 805-817.	1.5	51
51	Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress. <i>Proteomics</i> , 2006, 6, 6578-6587.	1.3	49
52	Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine. <i>Current Cancer Drug Targets</i> , 2009, 9, 398-418.	0.8	48
53	Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. <i>Anticancer Research</i> , 2002, 22, 3117-25.	0.5	45
54	Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 870-878.	2.2	43

#	ARTICLE	IF	CITATIONS
55	Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. <i>Anticancer Research</i> , 2007, 27, 1257-65.	0.5	42
56	TMEM25, REPS2 and Meis 1: Favourable Prognostic and Predictive Biomarkers for Breast Cancer. <i>Tumor Biology</i> , 2009, 30, 200-209.	0.8	41
57	Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. <i>Drug Discovery Today</i> , 2020, 25, 1124-1125.	3.2	41
58	The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells. <i>Cytotechnology</i> , 1993, 12, 289-314.	0.7	40
59	Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. <i>British Journal of Cancer</i> , 2017, 116, 620-625.	2.9	40
60	Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. <i>Investigational New Drugs</i> , 2010, 28, 433-444.	1.2	37
61	Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. <i>British Journal of Cancer</i> , 2010, 102, 1157-1162.	2.9	37
62	Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. <i>International Journal of Cancer</i> , 2004, 111, 484-493.	2.3	35
63	Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. <i>Cancer Biology and Therapy</i> , 2013, 14, 537-545.	1.5	35
64	Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2014, 74, 3821-3833.	0.4	34
65	EGFR and HER2 inhibition in pancreatic cancer. <i>Investigational New Drugs</i> , 2013, 31, 558-566.	1.2	28
66	Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. , 1997, 71, 907-915.		27
67	MAGEâ€4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. <i>International Journal of Cancer</i> , 2012, 130, 1991-2002.	2.3	26
68	The emerging world of microRNAs. <i>Anticancer Research</i> , 2006, 26, 4271-8.	0.5	26
69	Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 521-530.	1.1	25
70	Decreasing Txnip mRNA and Protein Levels in Pancreatic MIN6 Cells Reduces Reactive Oxygen Species and Restores Glucose Regulated Insulin Secretion. <i>Cellular Physiology and Biochemistry</i> , 2010, 25, 667-674.	1.1	25
71	Isosteviol Has Beneficial Effects on Palmitate-Induced Î±-Cell Dysfunction and Gene Expression. <i>PLoS ONE</i> , 2012, 7, e34361.	1.1	25
72	Pre-Clinical In Vitro Models Used in Cancer Research: Results of a Worldwide Survey. <i>Cancers</i> , 2021, 13, 6033.	1.7	24

#	ARTICLE	IF	CITATIONS
73	Mechanisms associated with loss of glucose responsiveness in beta cells. Transplantation Proceedings, 2004, 36, 1159-1162.	0.3	21
74	Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. International Journal of Cancer, 2017, 140, 2771-2784.	2.3	21
75	Evaluation of recombinant human transferrin (DeltaFerrinTM) as an iron chelator in serum-free media for mammalian cell culture. Cytotechnology, 2006, 51, 29-37.	0.7	20
76	Directed Differentiation of Mouse Embryonic Stem Cells into Pancreatic-Like or Neuronal- and Glial-Like Phenotypes. Tissue Engineering, 2007, 13, 2419-2430.	4.9	20
77	Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics and Proteomics, 2008, 5, 94-104.	1.0	16
78	Detection of Amplifiable mRNA Extracellular to Insulin-Producing Cells: Potential for Predicting Beta Cell Mass and Function. Clinical Chemistry, 2007, 53, 1936-1944.	1.5	15
79	Optimisation and comparison of orthogonal methods for separation and characterisation of extracellular vesicles to investigate how representative infant milk formula is of milk. Food Chemistry, 2021, 353, 129309.	4.2	15
80	Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction. Electrophoresis, 2008, 29, 4141-4149.	1.3	14
81	SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue. British Journal of Cancer, 2008, 98, 1641-1645.	2.9	14
82	The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line. BMC Bioinformatics, 2006, 7, 256.	1.2	13
83	The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. Proteomics, 2012, 12, 2115-2126.	1.3	13
84	Isolation, Structure Elucidation, and Cytotoxic Evaluation of Furanonaphthoquinones from in Vitro Plantlets and Cultures of Streptocarpus dunnii. Journal of Natural Products, 2011, 74, 82-85.	1.5	12
85	MicroRNA Profiling of Exosomes. Methods in Molecular Biology, 2017, 1509, 37-46.	0.4	11
86	European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD). European Journal of Pharmaceutical Sciences, 2017, 98, 1-3.	1.9	10
87	Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?. Drug Discovery Today, 2018, 23, 1267-1273.	3.2	10
88	Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine) Tj ETQq0 0 0 rgBT /Overlock 10 Tt	0.8	9
89	When E-Cadherin Becomes Unstuck in Cancer. New England Journal of Medicine, 2020, 383, 871-873.	13.9	9
90	Extracellular vesicle separation from milk and infant milk formula using acid precipitation and ultracentrifugation. STAR Protocols, 2021, 2, 100821.	0.5	9

#	ARTICLE	IF	CITATIONS
91	Receptor Tyrosine Kinases and Drug Resistance: Development and Characterization of In Vitro Models of Resistance to RTK Inhibitors. <i>Methods in Molecular Biology</i> , 2015, 1233, 169-180.	0.4	9
92	ENGINEERING VERO CELLS TO SECRETE HUMAN INSULIN. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2002, 38, 146.	0.7	8
93	Extracellular vesicles in blood: are they viable as diagnostic and predictive tools in breast cancer?. <i>Drug Discovery Today</i> , 2021, 26, 778-785.	3.2	8
94	Predictive biomarkers for dasatinib treatment in melanoma. <i>Oncoscience</i> , 2014, 1, 158-166.	0.9	8
95	A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?. <i>Anticancer Research</i> , 2007, 27, 1295-300.	0.5	8
96	Detecting de novo insulin synthesis in embryonic stem cell-derived populations. <i>Experimental Cell Research</i> , 2007, 313, 1405-1414.	1.2	7
97	miR-758-3p: a blood-based biomarker thatâ€™s influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome. <i>Oncotarget</i> , 2018, 9, 9379-9390.	0.8	7
98	Extracellular Vesicle Functionalized Melt Electrowritten Scaffolds for Bone Tissue Engineering. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100037.	1.7	7
99	MicroRNA Expression Analysis: Techniques Suitable for Studies of Intercellular and Extracellular MicroRNAs. <i>Methods in Molecular Biology</i> , 2011, 784, 99-107.	0.4	6
100	Analysis of Changes in Phosphorylation of Receptor Tyrosine Kinases: Antibody Arrays. <i>Methods in Molecular Biology</i> , 2015, 1233, 15-23.	0.4	5
101	A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker. <i>Translational Oncology</i> , 2022, 15, 101274.	1.7	5
102	Extracellular vesicles report on the MET status of their cells of origin regardless of the method used for their isolation. <i>Scientific Reports</i> , 2020, 10, 19020.	1.6	4
103	Evidence for the Need to Evaluate More Than One Source of Extracellular Vesicles, Rather Than Single or Pooled Samples Only, When Comparing Extracellular Vesicles Separation Methods. <i>Cancers</i> , 2021, 13, 4021.	1.7	4
104	Reverse-Transcriptase Polymerase Chain Reaction to Detect Extracellular mRNAs. <i>Methods in Molecular Biology</i> , 2011, 784, 15-25.	0.4	4
105	Characterisation of BHK-21 cells engineered to secrete human insulin. <i>Cytotechnology</i> , 2003, 41, 11-21.	0.7	3
106	Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome. <i>Methods in Molecular Biology</i> , 2017, 1509, 141-149.	0.4	3
107	Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. <i>Cancer Genomics and Proteomics</i> , 2005, 2, 43-52.	1.0	3
108	Challenges in molecular analysis for individualized cancer therapy. <i>Drug Discovery Today</i> , 2003, 8, 531.	3.2	2

#	ARTICLE	IF	CITATIONS
109	Western Blotting Analysis as a Tool to Study Receptor Tyrosine Kinases. <i>Methods in Molecular Biology</i> , 2011, 784, 109-121.	0.4	2
110	Expression in murine teratocarcinoma f9 cells of transcription factors involved in pancreas development. <i>Transplantation Proceedings</i> , 2004, 36, 1151-1158.	0.3	1
111	Miniaturized In Vitro Assays to Study Cellular Phenotypic Characteristics: Proliferation, Migration, Invasion, and Anoikis-Resistance. <i>Methods in Molecular Biology</i> , 2021, 2283, 225-232.	0.4	1
112	Receptor Tyrosine Kinase Targeting in Multicellular Spheroids. <i>Methods in Molecular Biology</i> , 2015, 1233, 161-168.	0.4	1
113	Analysis of Gene Expression as Relevant to Cancer Cells and Circulating Tumour Cells. <i>Methods in Molecular Biology</i> , 2011, 784, 55-75.	0.4	0
114	The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs.. <i>Journal of Clinical Oncology</i> , 2013, 31, 620-620.	0.8	0
115	Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells.. <i>Journal of Clinical Oncology</i> , 2015, 33, 614-614.	0.8	0
116	Gene Expression Microarray Technology: Some Applications in Lung Cancer Research. <i>Cancer Genomics and Proteomics</i> , 2006, 3, 197-202.	1.0	0